…with proposal to report all ‘adverse events’

Paul Smaglik

Nature, 1999, vol. 402, issue 6763, 707-707

Abstract: [WASHINGTON] The Recombinant DNA Advisory Committee of the National Institutes of Health has been urged to recommend that gene-therapy researchers be required to report all ‘adverse events’ occuring during their trials.

Date: 1999
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/45324 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:402:y:1999:i:6763:d:10.1038_45324

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/45324

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().